investig
risk
prognost
factor
pure
viral
sepsi
adult
patient
communityacquir
pneumonia
cap
use
definit
pure
viral
sepsi
found
patient
admit
emerg
depart
diagnosi
cap
cap
admit
intens
care
unit
diagnosi
viral
cap
data
indic
male
patient
age
year
increas
risk
viral
sepsi
investig
risk
prognost
factor
pure
viral
sepsi
adult
patient
communityacquir
pneumonia
cap
use
definit
pure
viral
sepsi
found
patient
admit
emerg
depart
diagnosi
cap
cap
admit
intens
care
unit
diagnosi
viral
cap
data
indic
male
patient
age
year
increas
risk
viral
sepsi
keyword
sepsi
viral
sepsi
viru
communityacquir
pneumonia
improv
molecular
diagnost
techniqu
increasingli
reveal
high
preval
viral
pneumonia
recent
year
global
estim
million
case
viral
pneumonia
occur
annual
incid
vari
season
geograph
locat
age
group
respiratori
virus
detect
etiolog
agent
almost
one
third
case
communityacquir
pneumonia
cap
patient
sever
cap
defin
microbi
etiolog
recent
jain
et
al
analyz
case
pneumonia
detect
intens
microbiolog
diagnosi
includ
viral
molecular
techniqu
microbi
etiolog
identifi
case
main
caus
respiratori
virus
bacteria
coinfect
indic
clear
promin
viral
etiolog
cap
often
complic
sepsi
multifactori
process
stage
necessari
provid
person
treatment
target
individu
need
viral
sepsi
defin
sever
inflammatori
respons
viral
infect
unlik
bacteri
sepsi
preval
adult
cap
unknown
aim
investig
preval
risk
prognost
factor
associ
pure
viral
sepsi
adult
patient
cap
use
third
intern
consensu
definit
sepsi
septic
shock
criteria
perform
retrospect
observ
studi
consecut
adult
patient
diagnosi
cap
admit
hospit
clinic
barcelona
emerg
depart
exclud
nonhospit
patient
sever
immunosuppress
activ
tuberculosi
viral
bacteri
coinfect
unavail
data
select
patient
pure
viral
cap
compar
without
sepsi
sever
cap
defin
accord
american
thorac
societyinfecti
diseas
societi
america
guidelin
sepsi
defin
presenc
pneumonia
increas
point
sequenti
organ
failur
assess
score
diagnosi
respiratori
viru
infect
made
basi
result
serolog
analysi
immunofluoresc
assay
cell
cultur
howev
diagnosi
base
result
polymeras
chain
reaction
pcr
andor
cultur
nasopharyng
swab
sampl
two
independ
nest
multiplex
realtim
pcr
test
use
detect
human
influenza
virus
b
c
respiratori
syncyti
viru
adenovirus
parainfluenza
virus
coronavirus
enterovirus
rhinovirus
b
c
criteria
etiolog
diagnosi
avail
previou
report
main
clinic
outcom
inhospit
mortal
secondari
outcom
includ
length
hospit
stay
intens
care
unit
icu
admiss
mortal
among
patient
admit
icu
length
icu
stay
need
mechan
ventil
mortal
mortal
patient
follow
one
year
public
purpos
studi
approv
ethic
committe
institut
registr
need
written
inform
consent
waiv
nonintervent
studi
design
logist
regress
analys
use
examin
associ
sepsi
risk
factor
first
risk
factor
test
individu
risk
factor
show
associ
univari
model
p
ad
multivari
model
final
backward
stepwis
select
p
p
use
determin
factor
associ
sepsi
gener
linear
model
analys
perform
determin
influenc
risk
factor
inhospit
mortal
model
defin
use
binomi
probabl
distribut
logit
link
function
use
invers
probabl
treatment
weight
iptw
account
bias
due
observ
confound
first
risk
factor
test
individu
second
propens
score
patient
sepsi
develop
iptw
use
propens
score
form
weight
final
weight
year
admiss
incorpor
multivari
weight
logist
regress
model
inhospit
mortal
includ
risk
factor
show
associ
univari
analys
p
backward
stepwis
elimin
perform
detect
factor
associ
inhospit
mortal
use
multipl
imput
method
miss
data
multivari
analys
level
signific
set
analys
perform
use
ibm
spss
statist
version
armonk
ny
identifi
consecut
patient
admit
emerg
depart
diagnosi
cap
studi
period
total
patient
hospit
found
pure
viral
cap
thirtysix
patient
sever
cap
among
case
pure
viral
cap
common
respiratori
virus
influenza
viru
coronaviru
observ
chang
preval
viral
cap
studi
period
p
mean
age
year
sex
male
patient
comorbid
chronic
respiratori
diseas
diabet
mellitu
frequent
despit
bacteri
pathogen
isol
patient
receiv
empir
antibiot
therapi
monotherapi
report
patient
fluoroquinolon
common
agent
administ
total
patient
receiv
combin
therapi
frequent
combin
compris
plu
macrolid
patient
plu
fluoroquinolon
median
length
hospit
stay
day
interquartil
rang
day
inhospit
mortal
patient
total
patient
admit
icu
requir
mechan
ventil
median
length
icu
stay
day
interquartil
rang
day
icu
mortal
patient
thirtyday
mortal
patient
mortal
among
patient
diagnosi
pure
viral
cap
present
sepsi
present
septic
shock
admiss
tabl
summar
main
clinic
characterist
sepsi
group
greater
mean
age
greater
proport
male
greater
preval
comorbid
especi
chronic
respiratori
diseas
compar
nonsepsi
group
statist
signific
differ
symptom
fever
cough
pleurit
pain
purul
expector
dyspnea
group
admiss
greater
proport
patient
sepsi
group
present
elev
respiratori
rate
lower
lymphocyt
level
compar
patient
nonsepsi
group
statist
signific
differ
distribut
respiratori
virus
group
thu
find
associ
type
viru
presenc
absenc
sepsi
nonsepsi
group
influenza
viru
found
patient
noninfluenza
viru
compar
respect
sepsi
group
p
patient
sepsi
group
classifi
pneumonia
sever
index
ivv
indic
sever
cap
overal
patient
receiv
antivir
therapi
oseltamivir
percentag
patient
receiv
antivir
therapi
similar
group
vs
p
fortyfour
patient
sepsi
treat
empir
antibiot
monotherapi
sepsi
group
receiv
fluoroquinolonebas
monotherapi
less
frequent
nonsepsi
group
vs
p
antimicrobi
therapi
inappropri
ie
nonconcord
publish
guidelin
case
sepsi
group
signific
differ
nonsepsi
group
among
variabl
associ
viral
sepsi
univari
logist
regress
analysi
age
year
male
sex
remain
independ
risk
factor
viral
sepsi
multivari
analysi
tabl
intern
valid
logist
regress
model
use
bootstrap
sampl
demonstr
robust
result
variabl
includ
model
small
confid
interv
ci
around
origin
coeffici
statist
signific
differ
observ
two
group
term
inhospit
mortal
icu
mortal
length
icu
stay
mortal
mortal
tabl
howev
patient
sepsi
show
longer
length
hospit
stay
frequent
admit
icu
need
frequent
invas
mechan
ventil
patient
without
sepsi
propensityadjust
logist
regress
multivari
analysi
inhospit
mortal
use
weight
data
exclus
patient
septic
shock
admiss
donotresuscit
order
pure
viral
sepsi
associ
inhospit
mortal
odd
ratio
ci
variabl
remain
signific
bootstrap
procedur
small
ci
around
origin
coeffici
studi
main
find
first
pure
viral
sepsi
defin
accord
criteria
found
patient
admit
diagnosi
cap
admit
abbrevi
ci
confid
interv
copd
chronic
obstruct
pulmonari
diseas
odd
ratio
variabl
analyz
univari
analysi
follow
age
sex
smoke
statu
alcohol
consumpt
influenza
vaccin
pneumococc
vaccin
previou
inhal
corticosteroid
therapi
previou
system
corticosteroid
therapi
previou
antibiot
therapi
last
week
chronic
pulmonari
diseas
chronic
cardiovascular
diseas
chronic
renal
diseas
chronic
liver
diseas
diabet
mellitu
chronic
neurolog
diseas
nurs
home
admiss
p
defin
probabl
sepsi
group
divid
probabl
nonsepsi
group
c
base
null
hypothesi
or
relat
explanatori
variabl
equal
uniti
ie
effect
patient
initi
receiv
noninvas
ventil
subsequ
need
intub
includ
invas
mechan
ventil
group
icu
diagnosi
pure
viral
cap
second
male
sex
age
year
shown
risk
factor
pure
viral
sepsi
third
pure
viral
sepsi
found
risk
factor
inhospit
mortal
sepsi
lifethreaten
organ
dysfunct
due
host
overwhelm
respons
infect
although
respiratori
virus
report
import
caus
agent
sever
cap
preval
pure
viral
sepsi
fulli
known
recent
publish
studi
investig
role
viru
detect
multiplex
pcr
nasopharyng
sampl
clinic
septic
patient
winter
season
author
report
respiratori
virus
includ
influenza
viru
human
metapneumoviru
coronaviru
respiratori
syncyti
viru
detect
adult
patient
sepsi
anoth
studi
montul
et
al
investig
predictor
sever
sepsi
patient
cap
found
patient
present
sever
sepsi
identifi
respiratori
virus
casual
agent
proport
patient
pure
viral
sepsi
slightli
higher
studi
popul
think
due
use
new
definit
montul
et
al
also
highlight
associ
older
age
develop
viral
sepsi
line
find
viral
sepsi
affect
patient
age
year
result
consist
data
show
increas
preval
chronic
condit
agerel
chang
immun
system
elderli
patient
suscept
infecti
diseas
sepsi
also
possibl
endothelium
fragil
popul
male
sex
anoth
risk
factor
pure
viral
sepsi
consist
data
men
typic
chronic
comorbid
higher
incid
cap
women
observ
viral
sepsi
risk
factor
inhospit
mortal
patient
without
septic
shock
data
support
previou
studi
respiratori
virus
frequent
found
critic
ill
patient
pneumonia
mortal
rate
significantli
differ
patient
bacteri
infect
viral
infect
highlight
need
identifi
patient
higher
risk
viral
sepsi
import
complet
microbiolog
diagnosi
case
cap
could
find
studi
address
issu
pure
viral
sepsi
defin
accord
criteria
case
cap
larg
inpati
adult
cohort
final
observ
patient
viral
cap
receiv
oseltamivir
therapi
without
differ
patient
without
sepsi
compar
previou
studi
popul
receiv
higher
proport
antivir
therapi
howev
futur
studi
need
investig
frequenc
antivir
therapi
use
among
patient
hospit
cap
high
sinc
current
guidelin
strongli
recommend
earli
treatment
oseltamivir
patient
influenza
limit
must
address
first
although
protocol
use
cap
diagnosi
hospit
chang
substanti
studi
discount
effect
chang
microbiolog
diagnosi
period
second
regard
microbiolog
diagnosi
morerapid
pcr
diagnost
test
influenza
viru
respiratori
syncyti
viru
use
influenza
season
third
indic
oseltamivir
therapi
extend
use
treat
sever
case
viral
infect
conclus
cohort
pure
viral
sepsi
affect
patient
diagnosi
viral
cap
support
import
stratifi
patient
risk
viral
sepsi
make
complet
microbiolog
diagnosi
case
cap
note
